Wyeth & Anor v Sigma Pharmaceuticals (Australia) Pty Limited; Wyeth & Anor v Alphapharm Pty Limited; Wyeth & Anor v Generic Health Pty Ltd

The High Court of Australia considered appeals by Wyeth, a pharmaceutical company, against decisions of the Federal Court of Australia. The dispute concerned the validity of certain patent claims held by Wyeth relating to the drug proton pump inhibitor, omeprazole. Wyeth alleged that the respondents, Sigma Pharmaceuticals (Australia) Pty Limited, Alphapharm Pty Limited, and Generic Health Pty Ltd, had infringed its patent rights by importing and supplying generic versions of omeprazole.

The central legal issues before the High Court were whether the patent claims were valid and, if so, whether the respondents' actions constituted infringement. Specifically, the court had to determine whether the patent claims were sufficiently clear and specific, and whether they were supported by the patent's description. The court also considered the scope of the patent claims and whether the generic products fell within that scope.

The High Court, in a joint judgment delivered by Gummow and Hayne JJ, found that the patent claims were invalid. Their Honours reasoned that the claims were not sufficiently clear and specific, and that the patent description did not adequately support the breadth of the claims made. The court applied principles of patent law concerning the requirements for clarity, specificity, and sufficiency of support in patent specifications, holding that the claims were too broad and lacked the necessary foundation in the disclosed invention. Consequently, the High Court allowed the appeals, setting aside the decisions of the Federal Court and holding that Wyeth's patent was invalid and therefore not infringed.